CSBio CSBio

X
[{"orgOrder":0,"company":"Polyneuron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polyneuron Receives Approval to Begin Clinical Study With PN-1007 in Anti-MAG Neuropathy","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Polyneuron Pharmaceuticals"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Almirall","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$23.6 million","newsHeadline":"Ichnos Sciences and Almirall Enter Into a Licensing Agreement for First-In-Class Il-1 RAP Antagonist Monoclonal Antibody","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Ichnos Sciences"},{"orgOrder":0,"company":"Vandria","sponsor":"Eurostars","pharmaFlowCategory":"D","amount":"$1.1 million","upfrontCash":"Undisclosed","newsHeadline":"Vandria Awarded \u20ac3.8M in Prestigious Innosuisse and Eurostars Grants to Advance Innovative Drug Programs for Age-Related Diseases of the CNS and Muscle","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Vandria"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Through financing, Vandria will be focusing on the mitophagy drug candidate VNA-052 to generate pre-clinical data in Vandria’s muscle program for the treatment of sporadic inclusion body myositis.

            Lead Product(s): VNA-052

            Therapeutic Area: Immunology Product Name: VNA-052

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Eurostars

            Deal Size: $1.1 million Upfront Cash: Undisclosed

            Deal Type: Financing February 08, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, Almirall is granted global rights to develop and commercialize ISB 880, monoclonal antibody for autoimmune diseases. Ichnos will retain rights for antibodies acting on the IL-1RAP pathway for oncology indications.

            Lead Product(s): ISB 880

            Therapeutic Area: Immunology Product Name: ISB 880

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Almirall

            Deal Size: Undisclosed Upfront Cash: $23.6 million

            Deal Type: Licensing Agreement December 14, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Regulatory authorities in France, the Netherlands and the UK have approved the clinical trial application for a phase I/IIa study of PN?1007 for the treatment of anti-MAG neuropathy.

            Lead Product(s): PN-1007

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 27, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY